Spectrum Pharmaceuticals to Develop Biosimilar Rituximab - - BioPharm International

ADVERTISEMENT

Spectrum Pharmaceuticals to Develop Biosimilar Rituximab


BioPharm Bulletin

California-based biopharmceutical company Spectrum Pharmaceuticals will develop a biosimilar version of Swiss pharmaceutical giant Roche Holding AG's monoclonal antibody drug rituximab. Spectrum aims to achieve this through a partnership with Viropro Inc (Irvine, CA).

Rituximab, which is sold as Rituxan by the Genentech unit of Swiss drugmaker Roche Holding, is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

The financial terms of the agreement weren't disclosed. Spectrum's deal with Viropro comes after Teva Pharmaceutical Industries launched efforts last May to develop a biosimilar of rituximab. Roche's rituximab loses patent protection in 2012.

“We are excited at the opportunity to develop our own proprietary biosimilar formulation of rituximab in anticipation of patent expirations for rituximab over the coming years,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc., in a company statement.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here